M&A Deal Summary |
|
---|---|
Date | 1994-07-12 |
Target | PCS Health Systems |
Sector | Healthcare Services |
Buyer(s) | Lilly |
Sellers(s) | McKesson |
Deal Type | Divestiture |
Deal Value | 4.4B USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1876 |
Sector | Life Science |
Employees | 43,000 |
Revenue | 34.1B USD (2023) |
Lilly discovers, develops, manufactures, and markets products in two business segments—human pharmaceutical products and animal health products. The mission of its human pharmaceutical business is to make medicines that help people live longer, healthier, more active lives. Most of the products Eli Lilly sells were discovered or developed by its own scientists, and the Company's success depends to a great extent on its ability to continue to discover, develop, and bring to market innovative new medicines. Eli Lilly's animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. Eli Lilly manufactures and distributes its products through facilities in the US, Puerto Rico, and 11 other countries. Lilly was founded in 1876 and is based in Indianapolis, Indiana.
DEAL STATS | # |
---|---|
Overall | 7 of 34 |
Sector (Healthcare Services) | 3 of 3 |
Type (Divestiture) | 1 of 6 |
State (Arizona) | 1 of 1 |
Country (United States) | 7 of 29 |
Year (1994) | 1 of 1 |
Size (of disclosed) | 4 of 20 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
1994-06-21 |
Guidant
Indianapolis, Indiana, United States Guidant Corporation pioneers lifesaving technology, giving an opportunity for better life today to millions of cardiac and vascular patients worldwide. The company, driven by a strong entrepreneurial culture of more than 10,000 employees, develops, manufactures and markets a broad array of products and services that enable less invasive care for some of life's most threatening medical conditions. |
Sell | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
1995-01-06 |
Pacific Biotech
San Diego, California, United States Pacific Biotech, Inc., is a developer and marketer of rapid diagnostic tests for the detection of pregnancy and infectious diseases such as strep throat, vaginal infections and mononucleosis. |
Sell | $4M |
Category | Company |
---|---|
Founded | 1833 |
Sector | Information Technology |
Employees | 45,000 |
Revenue | 309.0B USD (2024) |
McKesson is a health care services and information technology company. McKesson helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, health care information technology, and business and clinical services. McKesson was founded in 1833 and is based in Irving, Texas.
DEAL STATS | # |
---|---|
Overall | 1 of 19 |
Sector (Healthcare Services) | 1 of 4 |
Type (Divestiture) | 1 of 19 |
State (Arizona) | 1 of 1 |
Country (United States) | 1 of 10 |
Year (1994) | 1 of 1 |
Size (of disclosed) | 1 of 5 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
1972-01-01 |
PCS Health Systems
Scottsdale, Arizona, United States PCS Health Systems, Inc. is a pharmacy benefit manager, providing drug and health management solutions for health plans and patients. As America's premier pharmaceutical care system, PCS works to encourage proper drug use and helps to lower the cost of drugs for its clients. PCS manages and monitors approximately 300 million individual prescriptions each year representing $10 billion in drug expenditures. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
1996-01-01 |
Aesynt
Cranberry Township, Pennsylvania, United States Aesynt, Inc. provider of pharmacy automation and information management tools. The Company partners with healthcare organizations to fully optimize all medication forms enterprise-wide, driving cost reductions and improved patient safety. With major solutions for sterile compounding, enterprise-wide inventory management and medication dispensing, Aesynt is committed to developing innovative solutions to solve the most pressing challenges for the Company’s global healthcare partners. |
Buy | $65M |